Filing Details
- Accession Number:
- 0000950170-24-099275
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-20 18:31:14
- Reporting Period:
- 2024-08-16
- Accepted Time:
- 2024-08-20 18:31:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Inc. | BBIO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1742485 | Neil Kumar | C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-08-16 | 55,537 | $0.00 | 4,952,980 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-08-16 | 28,148 | $24.40 | 4,924,832 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2024-08-19 | 16,192 | $24.39 | 4,897,443 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-08-19 | 11,197 | $25.13 | 4,897,443 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-08-16 | 2,394 | $0.00 | 2,394 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-08-16 | 33,544 | $0.00 | 33,544 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-08-16 | 19,599 | $0.00 | 19,599 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,789 | No | 4 | M | Direct | ||
| 335,440 | No | 4 | M | Direct | ||
| 274,390 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,012,722 | Indirect | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. |
| Common Stock | 995,686 | Indirect | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
Footnotes
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 55,537 shares of Common Stock underlying the Reporting Person's RSUs.
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
- Represents the weighted average sale price of the shares sold ranging from $23.91 to $24.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- Represents the weighted average sale price of the shares sold ranging from $24.91 to $25.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
- The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Billionaire Hedge Funds
